<DOC>
	<DOCNO>NCT01705184</DOCNO>
	<brief_summary>At present , treatment non-squamous cell lung cancer base chemotherapy platinum eventually associate bevacizumab . A new treatment begin progression . In colo-rectal metastatic cancer , demonstrate first-line treatment could administer accord stop go strategy respect therapeutic break sequence identical treatment . During therapeutic break , treatment maintenance possibly well absence treatment . These plan benefit patient term efficiency also term toxicity , particular neurological . The question know strategy feasible lung cancer .</brief_summary>
	<brief_title>Re-introduction Pemetrexed Cisplatin With Prolonged Angiogenic Blocking Bevacizumab Advanced Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Non squamous non small cell lung cancer histologically cytologically confirm EGFR mutation . Stage IV NSCLC . Patient cerebral metastasis eligible metastasis asymptomatic . Measurable disease ( recist criterion ) Age â‰¥18 year PS0 1 Mixed cancer small cell non small cell squamous lung cancer . EGFR mutate cancer History malignant tumour except cervical basocellular cancer cancer cure least 5 year . Tumor invade big vessel proximal visible TDM . History adjuvant neoadjuvant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stop go</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Non-squamous</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>